Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy

Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 vaccination. Overall, 45 patients (median 72 years...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EJHaem 2023-02, Vol.4 (1), p.216-220
Hauptverfasser: Nguyen, Thi H. O., Lim, Chhay, Lasica, Masa, Whitechurch, Ashley, Tennakoon, Surekha, Saunders, Natalie R., Allen, Lilith F., Rowntree, Louise C., Chua, Brendon Y., Kedzierski, Lukasz, Tan, Hyon‐Xhi, Wheatley, Adam K., Kent, Stephen J., Karapanagiotidis, Theo, Nicholson, Suellen, Williamson, Deborah A., Slavin, Monica A., Tam, Constantine S., Kedzierska, Katherine, Teh, Benjamin W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 vaccination. Overall, 45 patients (median 72 years old) were recruited; the majority were male (71%), had CLL (76%) and were on zanubrutinib (78%). Seroconversion rates were 65% and 77% following two and three doses, respectively. CD4+ and CD8+ T‐cell response rates increased with third dose. In zanubrutinib‐treated patients, 86% developed either a humoral or cellular response. Patients on zanubrutinib developed substantial immune responses following two COVID‐19 vaccine doses, which further improved following a third dose.
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.639